Tosoh Launches Sales of SARS-CoV-2 Antibody Detection Reagents in Japan

Tokyo, Japan— Tosoh launched two kinds of immunoassay reagents that detect antibodies to nucleocapsid protein (NP) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) on December 2, 2020 for the Japan market. The product names for the Japan market are AIA-CL SARS CoV-2 NP-total antibody reagent and AIA-CL SARS CoV-2 NP-IgG antibody reagent. Please note that the overseas product names are subject to change.*

These reagents detect IgG and total antibodies (including IgG and IgM) against NP of the SARS-CoV-2, respectively. Both reagents are for use with Tosoh’s automated chemiluminescence enzyme immunoassay analyzers AIA®-CL2400 and another model of the AIA-CL analyzers. These two reagents require no manual preparation before use and offer results in as little as 15 minutes. They are expected to contribute to basic and clinical studies of SARS-CoV-2.

The research and development of these reagents was a result of collaborative effort by Tosoh, Yokohama City University, and Kanto Chemical Co., Inc., and was subsidized by the Japan Agency for Medical Research and Development (AMED). AMED supported this R&D under its fiscal year 2021 project as part of its research projects as countermeasures against infectious diseases such as viruses.

Tosoh is also working with Yokohama City University and other external entities on the R&D of a SARS-CoV-2 antigen test for its AIA-CL series analyzers. As ever, Tosoh aims to contribute to furthering medical research and practices.

*The two reagents referred to in this press release are for research use only.  Their performance in clinical use have not been established. These reagents, therefore, are not to be used for diagnostic or treatment purposes.

For more information on Tosoh’s lineup of AIA-CL analyzers and dedicated reagents, visit:

www.diagnostics.eu.tosohbioscience.com/our-products/immunoassay-analyzers

AIA-CL2400.jpgNP-Gトレイ写真201120.jpg

Name of Reagent

Applicable Sample Species

AIA-CL SARS CoV-2 NP-Total Antibody Reagent

Serum and EDTA plasma

AIA-CL SARS CoV-2 NP-IgG Antibody Reagent

Serum and EDTA plasma

 

*The two reagent products referred to in this press release are test reagents, the clinical usefulness of which has not been established. These reagents, therefore, are not to be used for diagnostic or treatment purposes.


TOSOH CORPORATION

WHO WE ARE

Tosoh Corporation is the parent of the Tosoh Group, which comprises over 100 companies worldwide and a multiethnic workforce of over 12,000 people and generated net sales of ¥786.1 billion (US$7.2 billion at the average rate of ¥108.7 to the US dollar) in fiscal 2020, ended March 31, 2020.

WHAT WE DO

Tosoh is one of the largest chlor-alkali manufacturers in Asia. The company supplies the plastic resins and an array of the basic chemicals that support modern life. Tosoh’s petrochemical operations supply ethylene, polyethylene, and functional polymers, while its advanced materials business serves the global semiconductor, display, and solar industries. Tosoh has also pioneered sophisticated bioscience systems that are used for the monitoring of life-threatening diseases. In addition, Tosoh demonstrates its commitment to a sustainable future in part by manufacturing a variety of eco-products.

Stock Exchange Ticker Symbol: 4042

DISCLAIMER

This document may contain forward-looking statements, including, without limitation, statements concerning product development, objectives, goals, and commercial introductions, which involve certain risks and uncertainties. Forward-looking statements are identified through the use of the word anticipates and other words of similar meaning. Actual results may differ significantly from the results expressed in forward-looking statements.

For more information, please contact

 

Gina Lau
International Public Relations
Tosoh Corporation

[email protected]
Tel: +81 3 5427 5118
Fax: +81 3 5427 5198